| | Quiz Page November 2008: A Family History of Kidney Failure and Hearing LossClinical Presentation  A 57-year-old woman presented to our hospital requesting a living kidney transplant from her husband. Her medical history included gradual hearing loss from her 30th year onward, necessitating hearing aids at the age of 35. Preterminal renal failure with proteinuria of 1.6 g/L of protein had been diagnosed 1 year earlier. A kidney biopsy could not be performed because of small kidneys. From age 20 years onward, she experienced bouts of urticaria and muscle pain. She had been admitted several times because of abdominal pain and increased C-reactive protein (CRP) levels, but no diagnosis could be made. In recent years, these symptoms had subsided. The patient's older brother developed end-stage renal disease 27 years ago at the age of 33 and received a kidney transplant. He also used hearing aids since age 30 years and had muscle pains and urticaria that improved after transplantation. The patient's younger brother had impaired kidney function and in 1987, at the age of 30 years, underwent kidney biopsy that was complicated by lethal bleeding. The mother, a third brother, and a sister were healthy, although all infrequently noticed urticaria. Figure 1 shows the pedigree for the members of this family and their symptoms. Because there were no contraindications, our patient received an uncomplicated kidney transplant. Posttransplantation kidney function was excellent. Nine months after transplantation, she reported a distended feeling after meals and intolerance for coffee and meat. She gradually lost 5 kg, developed iron deficiency anemia, and was found to have an increased CRP level of 82 mg/L. Upper and lower endoscopy and extensive radiological and laboratory investigations showed no abnormalities. Eleven months after transplantation, she presented with a minor stroke. The next day, after complete resolution of neurological abnormalities, she died suddenly. ■ What disorder is shown in the native kidney specimen obtained at autopsy (Fig 2A to B)? ■ What is the most likely diagnosis? ■ How can the diagnosis be confirmed? ■ Is treatment for this condition available? Discussion  What disorder is shown in the native kidney specimen obtained at autopsy? Congo Red staining of the native kidney shows amyloid in glomeruli, vessels, and interstitium (Fig 2A), and birefringence under polarized light (Fig 2B) confirms renal amyloidosis. Autopsy also showed an acute myocardial infarction, no cerebrovascular bleeding, no gastrointestinal abnormalities, and generalized AA amyloidosis, especially in vessels and native kidneys. The kidney allograft was normal. In retrospect, our patient appears to have had amyloidosis for a long time. Gastrointestinal manifestations of amyloidosis include bleeding caused by vascular fragility and loss of vasomotor responses to injury. In addition, gastroparesis, constipation, bacterial overgrowth, malabsorption, and pseudo-obstruction resulting from dysmotility occur. Amyloid deposition in the vessels explains the progressive kidney function impairment without nephrotic syndrome, coronary artery disease resulting in myocardial infarction, and likely cerebrovascular disease. The kidney biopsy specimen of the younger brother also showed amyloidosis. The occurrence of massive bleeding after the biopsy could have been related to amyloidosis. What is the most probable diagnosis? The observations are consistent with Muckle Wells syndrome (MWS), a rare autosomal dominant autoinflammatory disorder characterized by intermittent episodes of fever, urticarial rash, joint pain, progressive sensorineural deafness, and frequent development of AA-type amyloidosis of the kidneys and other organs.1, 2 Most patients present to rheumatologists, immunologists, or pediatricians, with renal manifestations occurring later.1, 2 MWS arises from a missense mutation in the gene NLRP3 (also referred to as CIAS1, NALP3, and PYPAF1) on chromosome 1, encoding a protein called cryopyrin. Cryopyrin is involved in apoptotic and inflammatory pathways through its upregulation of interleukin 1β (IL-1β).3 IL-1 increases the synthesis of serum amyloid A protein by hepatocytes during the acute-phase response. A persistently high serum amyloid A concentration is a prerequisite for the development of AA amyloidosis.4 Mutations in the NLRP3 gene are associated not only with MWS, but also with a spectrum of other autoinflammatory diseases. The clinical features of the various syndromes associated with mutations in this gene overlap to a great extent within and between families.3, 5 How can we confirm the diagnosis? DNA analysis of the NLRP3 gene from material from both our patient and her older brother showed a c.1241G→T mutation in exon 3 (numbering based on the A of the ATG translation initiation codon being position +1 [corresponding to nucleotide 753 of NM_004895.3]), causing an amino acid change from tryptophan to leucine at codon 414. This confirmed the diagnosis of MWS. Is treatment possible and indicated? Anakinra is a recombinant nonglycosylated homolog of human IL-1 receptor. It competitively inhibits binding of IL-1α and IL-1β to IL-1 receptor type 1. Successful responses to anakinra in patients with MWS have included recovery of hearing; decrease in CRP levels; disappearance of urticaria, arthralgias, and fever; and amelioration of nephrotic syndrome.6, 7, 8 Final Diagnosis  Muckle Wells syndrome. References  1. 1Fye KH. Diagnosis of Muckle Wells syndrome—30 Years later. J Rheumatol. 2007;34:2505–2506. 2. 2Messier G, Meyrier A, Rainfray M, Coste T, Callard P. Overt or occult renal amyloidosis in the Muckle-Wells syndrome. Kidney Int. 1988;34:566;. 3. 3Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319–325. MEDLINE |
CrossRef
4. 4Gillmore JD, Lovat LB, Persey R, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24–29. Abstract | Full Text |
Full-Text PDF (575 KB)
|
CrossRef
5. 5Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 2002;46:2445–2452. MEDLINE |
CrossRef
6. 6Maksimovic L, Stirnemann E, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle Wells and familial cold autoinflammatory syndromes. Rheumatology. 2008;47:309–310.
CrossRef
7. 7Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in Muckle-Wells syndrome. N Engl J Med. 2003;348:2583–2584.
CrossRef
8. 8Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 2006;54:1697–1700. MEDLINE |
CrossRef
Case provided and authored by Joke I. Roodnat MD, PhD,1 Esther de Theije-Kors, MD,2 Jan J. Weening, MD, PhD,3 Willem Weimar, MD, PhD,1 Paul L.A. van Daele, MD, PhD,4 Departments of 1Internal Medicine and Nephrology, 2Clinical Genetics, 3Pathology, and 4Internal Medicine and Immunology, Erasmus University Rotterdam, The Netherlands. Financial Disclosure: None. PII: S0272-6386(08)01098-6 doi:10.1053/j.ajkd.2008.07.005 © 2008 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved. | 
46 of 46
|
| |
|